Bim-mediated deletion of antigen-specific CD8⁺ T cells in patients unable to control HBV infection

A. Ross Lopes, Paul Kellam, Abhishek Das, Claire Dunn, Antonia Kwan, Joanna Turner, Dimitra Peppa, Richard J. Gilson, Adam Gehring, Antonio Bertolletti, and Mala K. Main

Division of Infection and Immunity and Centre for Sexual Health and HIV Research, University College London, London, United Kingdom. 2Camden Primary Care Trust, London, United Kingdom. 3Singapore Institute for Clinical Sciences, Agency for Science Technology and Research, Centros, Singapore.

HBV-specific CD8⁺ T cells are critical for a successful immune response to HBV infection. They are markedly diminished in number in patients who fail to control the virus, but the mechanisms resulting in their depletion remain ill defined. Here, we dissected the defective HBV-specific CD8⁺ T cell response associated with chronic HBV infection by gene expression profiling. We found that HBV-specific CD8⁺ T cells from patients with different clinical outcomes could be distinguished by their patterns of gene expression. Microarray analysis revealed that overlapping clusters of functionally related apoptotic genes were upregulated in HBV-specific CD8⁺ T cells from patients with chronic compared with resolved infection. Further analysis confirmed that levels of the proapoptotic protein Bcl2-interacting mediator (Bim) were upregulated in HBV-specific CD8⁺ T cells from patients with chronic HBV infection. Blocking Bim-mediated apoptosis enhanced recovery of HBV-specific CD8⁺ T cells both in culture and directly ex vivo. Consistent with evidence that Bim mediates apoptosis of CD8⁺ T cells expressing low levels of CD127 (IL-7R), the few surviving HBV-specific CD8⁺ T cells were CD127⁺ and had elevated levels of the antiapoptotic protein Mcl1, suggesting they were amenable to IL-7-mediated rescue from apoptosis. We therefore postulate that Bim-mediated attrition of HBV-specific CD8⁺ T cells contributes to the inability of these cell populations to persist and control viral replication.

Nonstandard abbreviations used: ALT, alanine transaminase; Bim, Bcl2-interacting mediator; CHB, chronic HBV; LCMV, lymphocytic choriomeningitis virus; SAM, significance analysis of microarrays.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 118:1835–1845 (2008). doi:10.1172/JCI33402.
most patients with high-level HBV replication; this paucity of HBV-specific CD8+ T cell responses has limited their characterization. In this study, we therefore applied gene expression profiling to allow simultaneous screening of a large number of potentially relevant pathways from small samples. Our strategy was to compare the gene expression profiles of HBV-specific CD8+ T cells from patients who had controlled HBV with those of the limited HBV-specific CD8+ T cells detectable in patients with CHB. Dual-color spotted glass microarrays were used, standardizing gene expression from the linearly amplified sample RNA against a universal reference.

HBV-specific CD8+ T cell responses were barely detectable in patients with high HBV load directly ex vivo. Instead, we took advantage of the few patients in this disease category from whom an adequate HBV-specific response (1%-17% of total CD8) could be detected after 10 days culture in vitro (Figure 1A and Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI33402DS1). These frequencies were postulated to be sufficient to detect changes that could be ascribed to the virus-specific component based on the results of a previous gene-array study of unsorted CD8+ cells (12). HBV-specific CD8+ T cells were restimulated with cognate peptide for 6 hours in order to focus the transcriptional profile on those genes activated or repressed upon antigen encounter (data not shown and refs. 13, 14). Sufficient high-quality RNA was obtained from such samples to successfully hybridize microarrays, 7 from patients with CHB and 12 from patients with resolved HBV infection. To ensure that the transcriptional profile reliably represented HBV-specific genes and not those from nonspecific cells in the short-term cell lines, microarray data was also obtained from sorted (>95% pure) HBV-specific CD8+ T cells from both groups of patients (Figure 1A).

An initial qualitative comparison of total noncompartmentalized microarray data from resolved and CHB-specific CD8+ T cells was carried out using self-organized mapping followed by hierarchical clustering (mode: average linkage) with Cluster (15). TreeView visualization demonstrated that the primary data set branched into 2 main groups (Figure 1B; groups C and R). The majority of samples in group C (6/8) and group R (10/11) derived from individuals with chronic and resolved infection, respectively.
The proapoptotic molecule Bim was upregulated at the protein level in HBV-specific CD8+ T cells from patients with chronic infection. Intrinsic apoptosis is determined by a carefully balanced and complex group of pro- and antiapoptotic proteins of the Bcl2 family. Of these proteins, Bim, short-listed by both methods of data analysis, had the highest statistical significance among the 76 genes selected and was therefore chosen for further study. Bim has been found to be critical for the elimination of CD8+ T cells in a mouse model of chronic viral infection (17) and is also required for deletion of CD8+ T cells following cross-presentation of soluble antigen in the periphery (18). The array data showed more Bim transcripts for samples from CHB patients than for the resolved samples; these data were validated by quantitative PCR on a subset of the same samples used for the arrays (data not shown).

Next, we sought to confirm these data at the protein level for a larger sample of patients who had HBV-specific CD8+ T cell populations after 10 days in vitro expansion that could be costained with a Bim mAb (19 responses from resolved patients, 25 from CHB patients). These patients were all HIV and HCV negative, had not received antiviral or immunosuppressive treatment, and had similar demographic characteristics (e.g., sex and age; see Table 1 and Supplemental Table 1). Peptide-specific IFN-γ production was used primarily to identify HBV-specific populations because we previously noted them to have a tetramer-negative, IFN-γ-positive phenotype in high-level carriers (1). Changes detected upon peptide restimulation should mimic those seen when the CD8+ T cells encounter their cognate antigen in the HBV-infected liver. Envelope 183-91— or core 18–27–specific responses were costained with a Bim mAb and examined by flow cytometry. Intracellular levels of Bim were stable over time in HBV-specific responses from patients who were sampled at repeated intervals while clinically stable (data not shown). HBV-specific CD8+ T cells from individuals with chronic infection were found to contain a significantly higher quantity of Bim protein compared with their counterparts in resolved individuals, in whom Bim was barely above background levels with an isotype control (Figure 2A; mean MFI of 52.3 compared with 20.7; P < 0.0001). Furthermore, an analysis of the chronic samples alone demonstrated that Bim expression was significantly higher in the HBV-specific population (IFN-γ+) compared with the total CD8+ T cell population of unrelated specificities (IFN-γ−) within individual patients (mean MFI of 52.3 compared with 33.6; P = 0.008) (Figure 2B).

The level of Bim expressed in HBV-specific CD8+ T cells within the group of chronic patients tested correlated with viral load (r = 0.7, P < 0.0001; Figure 2C). Bim expression was increased in chronic compared with resolved responses regardless of eAg status, although there was a nonsignificant trend to further increases in eAg-positive patients (Figure 2C).

To exclude a bias from in vitro culture, we confirmed our findings for differences in Bim expression of HBV-specific CD8+ T cells directly ex vivo. In order to detect sufficient HBV-specific respons-

### Table 1: Patient clinical details

<table>
<thead>
<tr>
<th>n</th>
<th>Sex (M)</th>
<th>Agea</th>
<th>VLb (IU × 10^a/ml)</th>
<th>ALTc</th>
<th>eAgd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolved</td>
<td>19</td>
<td>14</td>
<td>42 (24–69)</td>
<td>Negative</td>
<td>38 (10–74)</td>
</tr>
<tr>
<td>Chronic</td>
<td>25</td>
<td>17</td>
<td>39 (25–71)</td>
<td>73 (0.0001–510)</td>
<td>114 (17–554)</td>
</tr>
</tbody>
</table>

VL, viral load. aMean and range are shown.

The chronic patient whose HBV-specific CD8+ T cell gene expression branched with the resolved patients was the only CHB patient included in this analysis who did not have high HBV DNA (greater than 10^6 IU/ml). Thus, differences in gene expression induced upon HBV-specific activation were sufficient to allow segregation of samples according to clinical outcome. Among all the genes analyzed (5088 genes per array, spotted in duplicate), a clearly distinguishable cluster of genes was upregulated in chronic samples and downregulated in resolved samples (compared with reference RNA; Figure 1B). Closer inspection identified a subset of functionally related genes that exhibited a consistent divergence of expression level between the 2 groups. Of 20 genes in this hierarchical cluster with known functions, 16 had described roles in apoptosis. Two of these that are well characterized are the closely related BH3-only proapoptotic proteins Bim and Bid, the latter of which is the BH3-interacting domain death agonist.

In order to test for statistically robust differences in gene expression, normalized (median centered) cDNA array data were also processed by significance analysis of microarrays (SAM). This well-established bioinformatics tool utilized an algorithm (16) to calculate the fold change and statistical significance of any transcriptional differences between the resolved and chronic groups. Setting the acceptable median false discovery rate at 1.3%, we identified 105 differentially regulated genes (Supplemental Table 2). Seventy-six genes had increased expression, whereas 29 genes had reduced expression, in chronic compared with resolved samples from CHB patients than for the resolved samples; these data were validated by quantitative PCR on a subset of the same samples used for the arrays (data not shown).

A sample of 5 of the genes identified by both methods is presented in Figure 1D, with mean and SD of expression levels relative to the reference RNA (Mann-Whitney test). For each of these genes, expression was consistently increased in HBV-specific CD8+ T cells from CHB patients, both in samples from highly purified populations and from enriched 10-day cultures. These genes exhibiting highly significant increases in HBV-specific responses from chronic compared with resolved patients are all involved in lymphocyte apoptotic pathways. Thus, data from 2 independent analyses revealed that overlapping clusters of apoptosis-related transcripts were dysregulated in the HBV-specific CD8+ T cell response associated with chronicity.
es to co-stain with Bim directly ex vivo from the high-level HBV carriers of interest, we used pools of overlapping HBV peptides. We found that Bim levels were also significantly higher on HBV-specific CD8^+^ T cells responses sampled directly ex vivo from patients with chronic compared with resolved infection (Figure 2D). To circumvent any potential bias induced by the study of functional IFN-γ-producing cells, we also analyzed HBV-specific CD8^+^ T cells by tetramer staining. In the few patients with CHB in whom HBV-specific populations could be identified directly ex vivo with HLA-A2/HBV tetramers, we again found that Bim was significantly increased compared with such responses in resolved patients (Figure 2E). In contrast, HBV-specific CD8^+^ T cells sampled during acute symptomatic HBV infection at times of high viral load showed no induction of Bim expression compared with responses from the same patients after viremia had resolved (Figure 2F and Supplemental Figure 1). These data suggest that distortions in the interactions of the Bcl2 family mediated by an upregulation in Bim could be perturbing the fine equilibrium that ensures cell survival and instead favoring progression toward apoptosis during CHB.

Enhanced recovery of HBV-specific CD8^+^ T cells upon inhibition of apoptotic pathways in vitro. Bim is thought to act principally by activating Bax (19), permitting mitochondrial release of cytochrome c, which activates caspases, ultimately leading to cell death. We attempted to rescue HBV-specific CD8^+^ T cells that had upregulated Bim by interfering with caspase activity to block this intrinsic death cascade. Treatment of PBMCs from CHB patients with the irreversible pancaspase inhibitor zVAD-fmk prior to antigenic stimulation resulted in the expansion of a larger population of HBV-specific CD8^+^ T cells after 10 days of in vitro culture. Both core and envelope-specific responses could be reconstituted, with a mean 3-fold increase in virus-specific numbers compared with stimulation without the apoptosis inhibitor (Figure 3, A and B; P < 0.0001).

We then compared the rescue from Bim-mediated apoptosis that could be achieved for responses to each of the HBV proteins within individual patients. In order to do this, we applied 8 pools of peptides spanning the whole HBV genome, divided according to their protein specificity. In 4 patients with cAg^+^ high-level CHB, we were able to rescue additional responses to some or all of the pools of peptides spanning the different HBV proteins. An example shown in Figure 3C demonstrates that CD8^+^ T cell responses to only 3 pools were above background levels before rescue, whereas afterwards, responses were detectable in all pools. This suggested that responses were susceptible to Bim-mediated attrition regardless of their HBV specificity and that inhibition of this pathway held the potential to enhance the multispecificity of the HBV response.

The percentage of total CD8^+^ T cells did not increase in these experiments (data not shown; paired Student's t test; P = 0.48), suggesting that this rescue was restricted to HBV-specific populations. This was supported by the fact that influenza-specific CD8^+^ T-cell responses identified in the same patients with CHB infection were not increased by caspase inhibition (Figure 3D). In addition, HBV-specific CD8^+^ T cell responses expanded from patients who had resolved their infection were not prone to caspase-dependent apoptosis in vitro, as evidenced by their lack of rescue with the inhibitor (Figure 3E). Since Bim was already induced in vivo, our investigations were constrained by the need for downstream inhibition. However, we were able to block apoptosis directly downstream of Bim using a pentapeptide (VPLMK) that inhibits the proapoptotic mediator Bax by suppressing its mitochondrial translocation (20). This inhibitor was also capable of enhancing recovery of HBV-specific responses in culture (Figure 3F).

Rescue of HBV-specific CD8^+^ T cells from apoptosis directly ex vivo from patients with CHB. The experiments on short-term cell lines provided functional confirmation of the dysregulated apoptotic pathways identified by microarray profiling. They indicated that HBV-specific CD8^+^ T cells from patients with CHB infection are highly susceptible to apoptosis upon cognate-peptide restimulation in culture. To determine whether these populations were similarly apoptosis prone when circulating in patients with high viral load, we studied the effect of inhibition directly ex vivo. PBMCs from the same patients were stimulated with cognate peptide for 6 hours only in the presence of the caspase inhibitor and the responsive cells identified by intracellular IFN-γ production. Higher frequencies of both envelope and core-specific CD8^+^ T cells could be detected when caspase activity was blocked directly ex vivo (Figure 4). The fact that new functionally active responses became detectable after just 6 hours of culture indicated that these were generated by inhibition of apoptosis rather than an increase in proliferation. These data provided a direct ex vivo corroboration of our findings derived from HBV-specific CD8^+^ T cells cultured in vitro.

HBV-specific CD8^+^ T cells persisting in the face of high antigen load are selectively enriched for high expression of CD127 and Mcl1. Bim mediates death of CD8^+^ T cells expressing low levels of the IL-7Rα chain (CD127^−/) (21, 22), a phenotype typically seen in situations of chronic antigenic stimulation (23–25). We therefore hypothesized that the bulk of HBV-specific CD8^+^ T cells have been subjected to Bim-mediated deletion; the few persisting in these patients may have escaped the effects of upregulated Bim because of high levels of CD127 expression. This is supported by the recent finding that persisting HBV-specific CD8^+^ T cells maintain high levels of CD127 expression in patients with chronic infection (6). IL-7–receptor–mediated rescue
from Bim-induced apoptosis is regulated through the antiapoptotic molecule Mcl1, which binds specifically to Bim (26). To investigate whether persisting HBV-specific CD8+ T cells surviving after in vitro expansion without caspase inhibition had neutralized the proapoptotic drive of Bim, we examined their levels of Mcl1. Intracellular levels of McI1 were strikingly elevated in the core and envelope-specific CD8, with an MFI approximately double that seen in CD8+ T cells of the same specificity from patients who had resolved their HBV infections (Figure 5A). McI1 levels were also significantly higher (P < 0.0001) in HBV-specific CD8+ T cells than total CD8+ T cells in the same patients, whereas levels in influenza-specific CD8+ T cells were similar to those in total CD8+ T cells (Figure 5B). McI1 expression by HBV-specific CD8+ T cells correlated with viral load but was elevated in patients with chronic compared with resolved infection regardless of eAg status (Figure 5C). We confirmed that HBV-specific CD8+ T cells in patients with CHB infection were CD127hi, in line with published data (6). By costing HBV-specific CD8+ T cells for CD127 and McI1, we found that all CD127hi CD8+ T cells of this specificity expressed high intracellular levels of McI1, consistent with their rescue through this mechanism (Figure 5D).

Discussion

Using microarray profiling, we found that HBV-specific CD8+ T cells from patients with different clinical outcomes could be distinguished by their global patterns of gene expression. A number of genes were highly upregulated in the HBV-specific CD8+ T cells from patients with uncontrolled HBV replication. Among these, a cluster of functionally related apoptotic genes was identified, sharing the intrinsic Bcl2 pathway. The most highly and consistently upregulated was Bim, which was confirmed by intracellular staining of HBV-specific CD8+ T cells from an extended patient cohort to be increased in the attenuated response associated with chronicity. Bim is one of the proapoptotic BH3-only group of proteins from the Bcl2 family that plays a central role in the initiation of apoptosis signaling in lymphocytes (27, 28).

Bim has been shown in murine models to be required for shutdown of the CD8+ T cell response in the setting of a superantigenic stimulus (29) or an acute viral infection (30). Conversely, downregulation of Bim is critical for CD8+ T cell memory survival in the absence of antigen (31). More relevant to the situation of persistent infection with HBV, Bim has also recently been found to regulate CD8+ T cell responses during chronic LCMV infection in mice (17). Bim mediated predominant loss of an immunodominant LCMV-specific CD8+ T cell response, which parallels the situation in CHB infection in which responses to an immunodominant core epitope become undetectable in patients with high viral loads (5); these responses could be recovered in our study following downstream inhibition of Bim-mediated apoptosis.

Bim mediates apoptosis of CD127hi CD8+ T cells (22) and is the major inducer of virus-specific CD8+ T cell apoptosis of this phenotype (21). In accordance with this, we found that the few HBV-specific CD8+ T cells surviving in this setting had maintained expression of CD127 (the IL-7 receptor α chain). This paradoxical maintenance of a CD127hi phenotype in the face of a chronic viral infection has been noted recently in other studies of both HBV (6) and HCV (32–34) infection but is at odds with the characteristic low levels seen in other human chronic viral infections (24, 25). We speculate that the bulk of HBV-specific CD8+ T cells with low levels of CD127 have already been subjected to Bim-mediated deletion and the scanty populations we are able to study are the exceptions. These CD127hi CD8+ T cells may be able to escape sensitization to apoptosis through Bim upregulation (23).

Figure 3

Rescue of in vitro–cultured HBV-specific CD8+ T cells derived from individuals with CHB. Representative flow cytometry plots and cumulative data (below) showing the effect of pancaspase inhibition on the detection of envelope and core-specific CD8+ T cells (A and B, respectively) in 10-day peptide-stimulated cultures of PBMCs from individuals with chronic infection. Differences in responses with and without caspase inhibition were calculated with the paired Student’s t test (P < 0.0001). (C) Representative plots of the detection of HBV-specific CD8+ T cells in short-term lines of PBMCs from an individual with chronic infection utilizing pools of overlapping peptides corresponding to the HBV precore/core (PreC/C), X, envelope (E1p and E2p), and polymerase (P1–4) proteins with and without caspase inhibition. (D) Influenza A–specific CD8+ T cells detected in short-term lines from individuals with chronic infection ± caspase inhibition. (E) HBV-specific CD8+ T responses detected in short-term lines from resolved individuals with and without caspase inhibition. (F) HBV-specific CD8+ T cell rescue following specific inhibition of proapoptotic Bax in short-term lines from patients with chronic infection.

Figure 4

Direct ex vivo rescue of HBV-specific CD8+ T cells from patients with CHB. Representative flow cytometry plots and cumulative data (below) indicating direct ex vivo frequencies of HBV-specific CD8+ T cells in patients with chronic infection as detected following stimulation with viral peptide with and without treatment with the pancaspase inhibitor zVAD-fmk.
by maximizing rescue signals from IL-7 through the antiapoptotic protein Mcl1 (26), which we found to be upregulated in the same populations. Mcl1, induced by IL-7, has been shown to play an essential role in mature lymphocyte survival by counteracting the proapoptotic effects of Bim (26). These CD8+ T cells, in which Bim is already induced, would be poised to die once cytokine signals became limiting (35). Thus, a small subpopulation of HBV-specific CD8+ CD127+ cells may be selected by their ability to counteract Bim-mediated deletion. Alternatively, expression of CD127 may be a reflection of the recently primed status of the detectable HBV-specific CD8+ T cells from individuals with chronic HBV infection. Once the hierarchy of HBV-specific CD8+ T cell responses restricted by diverse HLA alleles has been better defined, it will be important to investigate whether Bim levels are lower in any subdominant responses that are identified in chronic infection.

A more compelling explanation is that Bim is upregulated in HBV-specific responses associated with chronicity as a result of defective intrahepatic antigen presentation or cross-presentation of HBV antigens; this remains purely speculative at present. Investigation into the molecular basis of cross-tolerance has revealed that Bim is required for peripheral deletion of CD8+ T cells following cross-presentation of soluble antigen (18). Cross-presentation was shown to result in defective priming, such that CD8+ T cells underwent initial proliferation followed by deletion, which was abrogated in Bim-deficient mice (18). Large amounts of soluble surface antigen and eAg are produced in HBV infection, and surface antigen can access the class I processing pathway for cross-presentation (39). Liver sinusoidal endothelial cells, which are well positioned to efficiently take up exogenous soluble antigen from the circulation or released from infected hepatocytes, have been shown to induce cross-tolerance in CD8+ T cells (40). Antigen that is endogenously processed and presented by hepatocytes has also been shown to induce initial proliferation followed by deletion or

Figure 5
Mcl1 and CD127 expression of HBV-specific CD8+ T cells. (A) Intracellular staining for Mcl1 in core and envelope-specific CD8+ T cells expanded in vitro from individuals with chronic and resolved infection (left) with cumulative data (right). (B) Summary of Mcl1 levels in HBV-specific (H), total (T), and influenza-specific (I) CD8+ T cells from individuals with persistent HBV infection. (C) Correlation between viral load and the level of Mcl1 expression in HBV-specific CD8+ T responses from individuals with chronic infection (left) and relative levels of Mcl1 expression in resolved and persistently infected patients segregated according to eAg status (right). (D) Intracellular stain for Mcl1 in CD127hi populations of HBV-specific and total CD8+ T cells. Error bars indicate mean ± SD.
anergy of responding CD8+ T cells (44, 45); whether this is mediated via Bim remains to be investigated. HBV-specific CD8+ T cells recognize antigen presented by HBV-infected human hepatocytes (46) and upon recognition become highly prone to apoptosis (A. Bertoletti et al., unpublished observations).

By blocking Bim-mediated apoptosis, we were able to enhance recovery of HBV-specific CD8+ T cells in culture, providing functional confirmation of our microarray data and highlighting a potential strategy to enhance recovery of these populations. Blocking of PD-1/PD-L1 interactions has also recently been found to reverse sustained antiviral efficacy.

Some of the HBV-specific CD8+ specific responses were not recovered by blocking the PD-1 pathway in vitro. It is possible that in vivo, potentially via an alternative mechanism, these responses can be reconstituted in vivo, as suggested by the observation that the proportion of HBV-specific CD8+ T cells that were CD69+ or IFN-γ producing in these patients is likely to have already been tolerated by the persistent high antigen load that is associated with chronic infection. The long-term influence of the PD-1/PD-L1 pathway on HBV infection and disease is uncertain, but may contribute to the persistence of the viral infection.

We would only expect to be able to achieve a limited amount of reconstitution ex vivo, since most HBV-specific CD8+ T cells are likely to have already been tolerated by the persistent high antigen load in vivo. The short lifespan of HBV-specific responses reconstituted during antiviral therapy (11) suggests that a short-term reduction in viral load does not allow a full recovery of their propensity to apoptosis. A strategy that could block Bim induction (for example, with short-term use of cyclosporin A or FK506; ref. 37) rather than preventing apoptosis downstream once it is upregulated holds greater promise for reconstituting effective HBV-specific responses. This raises the possibility of specifically reprogramming the HBV-specific CD8+ T cell susceptibility to Bim-mediated apoptosis in patients following the use of potent antivirals to first reduce viral load.

In conclusion, the profound HBV-specific CD8+ T cell hyporesponsiveness found in chronic infection is likely to represent the combined effect of multiple deletion and suppressor mechanisms related to the exceptionally high level of antigen load in these patients. In this study, a global, unbiased approach to dissecting these mechanisms highlighted a dysregulated apoptotic pathway. We postulate that cross-presentation of HBV antigens and subsequent Bim-mediated deletion contributes to the failure of CD8+ T cell responses in CHB infection. Interruption of this tolerizing mechanism may provide a new strategy to reconstitute more effective HBV responses in order to achieve a treatment strategy with sustained antiviral efficacy.

**Methods**

**Patients.** Forty-four patients were recruited with written informed consent; the Camden and Islington Primary Care Trust Local Research Ethics Committee approved this study (see Table 1 and Supplemental Table 1). HLA-A2 status was determined by flow cytometry (HLA-A2 surface staining; Abd Serotec). Nineteen patients had clinical, biochemical, and virological evidence of resolved HBV infection (recovery from acute hepatitis, normal alanine transaminase (ALT), anti-HBcAb, HBsAg, HBV DNA undetectable); of these, 3 (R7, R13, and R17; Supplemental Table 1) were also sampled during the acute symptomatic phase of primary HBV infection (anti-HBc IgM+, SAg+; HBV DNA high, ALT high). Twenty-five patients had clinical, biological, and virological evidence of CHB infection (HBsAg+, HBV DNA+, HBeAg-). These patients had no other causes of liver damage, were negative for HIV-1 and -2, HCV, and delta virus and had not received antiviral therapy or immunosuppressive drugs. HbsAg, anti-HbsAb, total and immunoglobulin M anti-HBcAb, HBeAg, anti-HBeAb, anti-HDV, anti-HCV, anti-HIV-1, and HIV-2 were determined by commercial enzyme immunoassays (Murex Diagnostics; Abbott; Ortho-Clinical Diagnostics; and Sanofi Diagnostics Pasteur). Serum HBV DNA load was determined by real-time PCR.

**Antibodies and reagents used.** Antibodies used were CD3-perCpCy5.5, CD8-Cy5.5, CD8-APC, CD127-PE, CD8PerCp-Cy5.5, IFN-γ-APC and Cytofix/Cytoperm, 2VAD-fmk (BD Biosciences), IFN-γ-PE (R&D Systems), IFN-γ Secretion Assay Cell Enrichment and Detection kit (Miltenyi Biotech), Bim unconjugated (Alexis Biochemicals; Axxora), goat anti-rat IgG2a FITC (Bethyl Laboratories), Mc11 unconjugated, goat anti-rabbit FITC (Insight Biotechnologies), brefeldin A, saponin, PBS (Sigma-Aldrich), and aMEM (Invitrogen). HBV c18-27, envelope 183-191, and polymerase 455–463 multimers were from Proimmune or were kindly provided by Alison Turner and Paul Klenerman (Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom).

**Cell isolation, culture, and staining.** PBMCs were separated from EDTA-treated venous blood on Ficoll. Virus-specific CD8-enriched lines were generated by culturing total PBMCs (0.3 × 10⁶/200 μl/well) with 1 μM peptide (HBV core 18–27, HBV envelope 183-191 [genotype D/serotype ayw]) or influenza A Mps86-66; Proimmune) in aMEM/10% FCS (Gibco; Invitrogen). HBV c18–27, envelope 183-191, and polymerase 455–463 multimers were from Proimmune or were kindly provided by Alison Turner and Paul Klenerman (Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom).

**Rescue of HBV-specific CD8+ T cells.** PBMCs were stimulated with individual viral peptides (HBV core 18-27 or HBV envelope 183-191; Proimmune) or pools of 15 mer peptides overlapping by 10 residues spanning the major proteins of HBV genotype B (Mimotopes); 8 pools comprised precore and core (peptides 1-6 and 1–35), X (peptides 1–29), envelope pool 1 (peptides 1–38), envelope pool 2 (peptides 39–76), polymerase pool 1 (peptides 1–42), polymerase pool 2 (peptides 43–84), polymerase pool 3 (peptides 85–126), and polymerase pool 4 (peptides 127–167). Stimulated cells were simultaneously treated with and without the pancaspase inhibitor zVAD-fmk (50 μM) or Bax inhibitor peptide VPMLK (20) (50 μM); culture medium was replenished with the inhibitor every 3 days and with IL-2 on day 4. IFN-γ virus-specific CD8+ T cells were determined by flow cytometry after 10 days as described above. Direct ex vivo analysis of IFN-γ, Bim, or Mc11 after permeabilization, with appropriate negative controls for nonspecific staining.

**Microarray analysis.** For microarray applications, PBMCs (0.5 × 10⁶ cells) were lysed following peptide restimulation (5 hours) and mRNA extracted (Dynal mRNA Direct microkit; Invitrogen) according to the manufacturer’s instructions. Highly purified virus-specific CD8+ T cells were obtained by FACs sorting with a MoFlo Sorter (Dako) or by magnetic bead purification after labeling cells with multimers (Proimmune) or IFN-γ catch reagent (Miltenyi Biotech) according to the manufacturers’ instructions. Dual-color microarray analysis was conducted as previously described.


